Literature DB >> 10712203

Functional analysis of the neurofibromatosis type 2 protein by means of disease-causing point mutations.

R P Stokowski1, D R Cox.   

Abstract

Despite intense study of the neurofibromatosis type 2 (NF2) tumor-suppressor protein merlin, the biological properties and tumor-suppressor functions of merlin are still largely unknown. In this study, we examined the molecular activities of NF2-causing mutant merlin proteins in transfected mammalian cells, to elucidate the merlin properties that are critical for tumor-suppressor function. Most important, we found that 80% of the merlin mutants studied significantly altered cell adhesion, causing cells to detach from the substratum. This finding implies a function for merlin in regulating cell-matrix attachment, and changes in cell adhesion caused by mutant protein expression may be an initial step in the pathogenesis of NF2. In addition, five different mutations in merlin caused a significant increase in detergent solubility of merlin compared to wild type, indicating a decreased ability to interact with the cytoskeleton. Although not correlated to the cell-adhesion phenotype, four missense mutations decreased the binding of merlin to the ERM-interacting protein EBP-50, implicating this interaction in merlin inhibition of cell growth. Last, we found that some NF2 point mutations in merlin most closely resembled gain-of-function alleles in their cellular phenotype, which suggests that mutant NF2 alleles may not always act in a loss-of-function manner, as had been assumed, but may include a spectrum of allelic types with different phenotypic effects on the function of the protein. In aggregate, these cellular phenotypes provide a useful assay for identifying the functional domains and molecular partners necessary for merlin tumor-suppressor activity.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10712203      PMCID: PMC1288182          DOI: 10.1086/302812

Source DB:  PubMed          Journal:  Am J Hum Genet        ISSN: 0002-9297            Impact factor:   11.025


  61 in total

1.  Defects in neurofibromatosis 2 protein function can arise at multiple levels.

Authors:  D H Gutmann; R T Geist; H m Xu; J S Kim; S Saporito-Irwin
Journal:  Hum Mol Genet       Date:  1998-03       Impact factor: 6.150

2.  Merlin differentially associates with the microtubule and actin cytoskeleton.

Authors:  H M Xu; D H Gutmann
Journal:  J Neurosci Res       Date:  1998-02-01       Impact factor: 4.164

3.  Regulation of the neurofibromatosis type 2 tumor suppressor protein, merlin, by adhesion and growth arrest stimuli.

Authors:  R J Shaw; A I McClatchey; T Jacks
Journal:  J Biol Chem       Date:  1998-03-27       Impact factor: 5.157

4.  Loss of merlin-p85 protein complex in NF2-related tumors.

Authors:  H Takeshima; T Nishi; K Yamamoto; T Kino; H Nakamura; H Saya; M Kochi; J I Kuratsu; Y Ushio
Journal:  Int J Oncol       Date:  1998-05       Impact factor: 5.650

5.  Neurofibromatosis 2 tumour suppressor schwannomin interacts with betaII-spectrin.

Authors:  D R Scoles; D P Huynh; P A Morcos; E R Coulsell; N G Robinson; F Tamanoi; S M Pulst
Journal:  Nat Genet       Date:  1998-04       Impact factor: 38.330

6.  Isolation and characterization of Schwann cells from neurofibromatosis type 2 patients.

Authors:  C Rosenbaum; L Kluwe; V F Mautner; R E Friedrich; H W Müller; C O Hanemann
Journal:  Neurobiol Dis       Date:  1998-07       Impact factor: 5.996

7.  Genotype/phenotype correlations in type 2 neurofibromatosis (NF2): evidence for more severe disease associated with truncating mutations.

Authors:  D G Evans; L Trueman; A Wallace; S Collins; T Strachan
Journal:  J Med Genet       Date:  1998-06       Impact factor: 6.318

Review 8.  Structure-function relationships in the ezrin family and the effect of tumor-associated point mutations in neurofibromatosis 2 protein.

Authors:  O Turunen; M Sainio; J Jääskeläinen; O Carpén; A Vaheri
Journal:  Biochim Biophys Acta       Date:  1998-09-08

9.  The carboxyl-terminal region of EBP50 binds to a site in the amino-terminal domain of ezrin that is masked in the dormant molecule.

Authors:  D Reczek; A Bretscher
Journal:  J Biol Chem       Date:  1998-07-17       Impact factor: 5.157

10.  Structural analysis of Drosophila merlin reveals functional domains important for growth control and subcellular localization.

Authors:  D R LaJeunesse; B M McCartney; R G Fehon
Journal:  J Cell Biol       Date:  1998-06-29       Impact factor: 10.539

View more
  16 in total

1.  The neurofibromatosis type 2 gene product, merlin, reverses the F-actin cytoskeletal defects in primary human Schwannoma cells.

Authors:  Anne-Marie Bashour; J-J Meng; Wallace Ip; Mia MacCollin; Nancy Ratner
Journal:  Mol Cell Biol       Date:  2002-02       Impact factor: 4.272

2.  Unfurling of the band 4.1, ezrin, radixin, moesin (FERM) domain of the merlin tumor suppressor.

Authors:  S D Yogesha; Andrew J Sharff; Marco Giovannini; Gerard Bricogne; Tina Izard
Journal:  Protein Sci       Date:  2011-11-09       Impact factor: 6.725

3.  A tight junction-associated Merlin-angiomotin complex mediates Merlin's regulation of mitogenic signaling and tumor suppressive functions.

Authors:  Chunling Yi; Scott Troutman; Daniela Fera; Anat Stemmer-Rachamimov; Jacqueline L Avila; Neepa Christian; Nathalie Luna Persson; Akihiko Shimono; David W Speicher; Ronen Marmorstein; Lars Holmgren; Joseph L Kissil
Journal:  Cancer Cell       Date:  2011-04-12       Impact factor: 31.743

4.  Microtubule-mediated transport of the tumor-suppressor protein Merlin and its mutants.

Authors:  Lorena B Benseñor; Kari Barlan; Sarah E Rice; Richard G Fehon; Vladimir I Gelfand
Journal:  Proc Natl Acad Sci U S A       Date:  2010-04-05       Impact factor: 11.205

5.  Expression of the cytoskeleton linker protein ezrin in human cancers.

Authors:  Benjamin Bruce; Gaurav Khanna; Ling Ren; Goran Landberg; Karin Jirström; Charles Powell; Alain Borczuk; Evan T Keller; Kirk J Wojno; Paul Meltzer; Kristin Baird; Andrea McClatchey; Anthony Bretscher; Stephen M Hewitt; Chand Khanna
Journal:  Clin Exp Metastasis       Date:  2007-03-17       Impact factor: 5.150

6.  The neurofibromatosis 2 protein product merlin selectively binds F-actin but not G-actin, and stabilizes the filaments through a lateral association.

Authors:  M F James; N Manchanda; C Gonzalez-Agosti; J H Hartwig; V Ramesh
Journal:  Biochem J       Date:  2001-06-01       Impact factor: 3.857

7.  Binding of the merlin-I product of the neurofibromatosis type 2 tumour suppressor gene to a novel site in beta-fodrin is regulated by association between merlin domains.

Authors:  G W Neill; M R Crompton
Journal:  Biochem J       Date:  2001-09-15       Impact factor: 3.857

8.  FERM domain phosphoinositide binding targets merlin to the membrane and is essential for its growth-suppressive function.

Authors:  Timmy Mani; Robert F Hennigan; Lauren A Foster; Deborah G Conrady; Andrew B Herr; Wallace Ip
Journal:  Mol Cell Biol       Date:  2011-03-14       Impact factor: 4.272

9.  Loss of heterozygosity on long arm of chromosome 22 in sporadic colorectal carcinoma.

Authors:  Chong-Zhi Zhou; Zhi-Hai Peng; Fang Zhang; Guo-Qiang Qiu; Lin He
Journal:  World J Gastroenterol       Date:  2002-08       Impact factor: 5.742

10.  p21-Activated kinases are required for transformation in a cell-based model of neurofibromatosis type 2.

Authors:  Hoi Yee Chow; Dina Stepanova; Jennifer Koch; Jonathan Chernoff
Journal:  PLoS One       Date:  2010-11-02       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.